LPL Financial LLC grew its stake in Sanofi (NASDAQ:SNY - Free Report) by 12.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,284,096 shares of the company's stock after acquiring an additional 142,290 shares during the period. LPL Financial LLC owned 0.05% of Sanofi worth $61,932,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of SNY. Raymond James Financial Inc. acquired a new stake in Sanofi during the 4th quarter worth approximately $135,933,000. Boston Partners lifted its holdings in shares of Sanofi by 86.4% during the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after buying an additional 2,501,073 shares in the last quarter. Magnetar Financial LLC boosted its position in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the period. DAVENPORT & Co LLC grew its stake in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company's stock valued at $110,715,000 after acquiring an additional 664,455 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of Sanofi by 36.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company's stock worth $93,774,000 after purchasing an additional 514,542 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. StockNews.com cut Sanofi from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Sanofi presently has an average rating of "Moderate Buy" and a consensus price target of $62.50.
Get Our Latest Research Report on Sanofi
Sanofi Price Performance
Sanofi stock traded down $0.36 during midday trading on Monday, reaching $55.46. The company's stock had a trading volume of 1,559,214 shares, compared to its average volume of 2,266,135. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market cap of $140.75 billion, a PE ratio of 22.27, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The business has a 50-day moving average price of $55.22 and a 200-day moving average price of $52.75.
Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
